{
    "clinical_study": {
        "@rank": "156440", 
        "acronym": "FVD", 
        "arm_group": [
            {
                "arm_group_label": "FVD regimen", 
                "arm_group_type": "Experimental", 
                "description": "FVD regimen(fotemustine, teniposide and dexamethasone),fotemustine 100mg/m2 d1 ivgtt,teniposide 60mg/m2 d2-4 ivgtt,dexamethasone 40mg d1-5 ivgtt.Continued use to the end of chemotherapy .Every 21 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles."
            }, 
            {
                "arm_group_label": "HD-MTX-Ara-C regimen", 
                "arm_group_type": "Experimental", 
                "description": "high-does metrotrexate 3.5g/m2 d1 ivgtt 6h,cytarabine 1g/m2 bid d2-3.Continued use to the end of chemotherapy .Every 21 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the efficacy and safety of FVD regiment\n      (fotemustine, teniposide and dexamethasone ) for patients with primary CNS lymphoma."
        }, 
        "brief_title": "Treatment of Primary CNS Lymphoma", 
        "completion_date": {
            "#text": "June 2020", 
            "@type": "Anticipated"
        }, 
        "condition": "Primary CNS Lymphoma (PCNSL)", 
        "condition_browse": {
            "mesh_term": "Lymphoma"
        }, 
        "detailed_description": {
            "textblock": "Primary CNS lymphoma (PCNSL) is a rare B-cell variant of non-Hodgkin lymphoma that is\n      confined to the brain, leptomeninges, spinal cord, and eyes. The optimum treatment for\n      patients with PCNSL remains challenging and at present there is no universally accepted\n      therapeutic approach for patients with newly diagnosed disease. The purpose of this study is\n      to evaluate the efficacy and safety of FVD regiment(fotemustine, teniposide and\n      dexamethasone)contrast with HD-MTX-Ara-C program for patients with primary CNS lymphoma."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:Age range 14-60 years old; ECOG performance status 0-2; Estimated\n        survival time > 3 months Histological confirmed PCNSL None of chemotherapy or radiotherapy\n        has been previously used None of chemotherapy contraindication: hemoglobin \u2265 90 g/dl,\n        neutrophil \u2265 1.5\u00d7109/L, platelet \u2265 100\u00d7109/L, ALT and AST \u2264 2\u00d7ULN, serum bilirubin \u2264\n        1.5\u00d7ULN, serum creatine \u2264 1.5\u00d7upper limitation of normal (ULN), Serum Albumin \u2265 30g/L,\n        serum plasminogen is normal (Inclusion Criteria of 1,3,6 groups ) At least one measurable\n        lesion None of other serious diseases, cardiopulmonary function is normal Pregnancy test\n        of women at reproductive age must be negative Patients could be followed up None of other\n        relative treatments including the traditional Chinese medicine, immunotherapy,biotherapy\n        except anti-bone metastasis therapy and other symptomatic treatments.\n\n        volunteers who signed informed consent. -\n\n        Exclusion Criteria:Disagreement on blood sample collection Patients allergic of any of\n        drug in this regimen or with metabolic disorder Pregnant or lactating women Serious\n        medical illness likely to interfere with participation Serious infection Primitive or\n        secondary tumors of central nervous system Chemotherapy or radiotherapy contraindication\n        The evidence of peripheral nervous disorder or dysphrenia patients participating in other\n        clinical trials patients taking other antitumor drugs patients estimated to be unsuitable\n        by investigato\n\n        -"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "14 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01960192", 
            "org_study_id": "hnslblzlzx2011-6"
        }, 
        "intervention": [
            {
                "arm_group_label": "HD-MTX-Ara-C regimen", 
                "description": "high-does metrotrexate 3.5g/m2 d1 ivgtt 6h,cytarabine 1g/m2 bid d2-3.Continued use to the end of chemotherapy .Every 21 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles", 
                "intervention_name": "HD-MTX-Ara-C regimen", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "FVD regimen", 
                "description": "FVD regimen(fotemustine, teniposide and dexamethasone),fotemustine 100mg/m2 d1 ivgtt,teniposide 60mg/m2 d2-4 ivgtt,dexamethasone 40mg d1-5 ivgtt.Continued use to the end of chemotherapy .Every 21 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles", 
                "intervention_name": "FVD regimen", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cytarabine", 
                "Fotemustine", 
                "Dexamethasone"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "primary CNS lymphoma;chemotherapy;", 
            "RR;PFS;OS"
        ], 
        "lastchanged_date": "October 9, 2013", 
        "location": {
            "contact": {
                "email": "mingzhi_zhang@126.com", 
                "last_name": "Mingzhi Zhang, Pro,Dr", 
                "phone": "13838565629"
            }, 
            "facility": {
                "address": {
                    "city": "Zhengzhou", 
                    "country": "China", 
                    "state": "Henan", 
                    "zip": "450052"
                }, 
                "name": "Oncology Department of The First Affiliated Hospital of Zhengzhou University"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Prospective Study of FVD Program and HD-MTX-Ara-C Program Contrast in the Treatment of PCNSL Lymphoma.", 
        "overall_contact": {
            "email": "Mingzhi_zhang@126.com", 
            "last_name": "Mingzhi zhang, Pro\uff0cDr", 
            "phone": "13838565629"
        }, 
        "overall_official": {
            "affiliation": "The First Affiliated Hospital of Zhengzhou University", 
            "last_name": "Mingzhi Zhang, Pro,Dr", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Progression-free survival", 
            "safety_issue": "No", 
            "time_frame": "up to end of follow-up-phase (approximately 24 months)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01960192"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Zhengzhou University", 
            "investigator_full_name": "Mingzhi Zhang", 
            "investigator_title": "the director of oncology department of the first affiliated hospital", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "response rate", 
                "safety_issue": "No", 
                "time_frame": "every 6 weeks,up to completion of treatment(approximately 18 weeks )"
            }, 
            {
                "measure": "overall survival", 
                "safety_issue": "No", 
                "time_frame": "up to the date of death (approximately 5 years)"
            }, 
            {
                "measure": "median survival time", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }
        ], 
        "source": "Zhengzhou University", 
        "sponsors": {
            "collaborator": {
                "agency": "Zhengzhou University", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Mingzhi Zhang", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}